Agilvax
Private company that discovers and develops immunotherapies to combat cancer & targeted vaccines against infectious diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€5—8m (Dealroom.co estimates Jan 2020.)
Albuquerque New Mexico (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | $1.2m | Early VC | |
$2.0m | Series A | ||
$500k | Series A | ||
$2.3m | Grant | ||
$2.0m | Grant | ||
N/A | $1.5m | Series A | |
Total Funding | €8.6m |
Recent News about Agilvax
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.